The latest research, news, and more from GeoInvesting for Soligenix, Inc. (SNGX) /companies/sngx_soligenix__inc_/overview en-us Fri, 03 Apr 2026 23:33:41 GMT Fri, 03 Apr 2026 23:33:41 GMT 120 52966Wed, 27 Feb 2013 05:00:00 GMT<P>"Soligenix is a development stage biopharmaceutical company developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec<SUP>&#174;</SUP>), as well as developing its novel innate defense regulator (IDR) technology for the treatment of oral Mucositis (SGX942).&nbsp;&nbsp; &nbsp;&nbsp;</P> <P>Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax&#8482;, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax&#8482;, a vaccine against anthrax exposure. RiVax&#8482; has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax&#8482; and VeloThrax&#8482; are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax&#8482;. Soligenix is also developing OrbeShield&#8482; for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShield&#8482; has previously demonstrated statistically significant preclinical survival results in two separate canine GI ARS studies funded by the NIH." (source: press)</P>/companies/sngx_soligenix__inc_/overview52968Fri, 26 Jun 2015 04:00:00 GMT<P>Disclosure: GeoInvesting is providing this information for your edification and in no way has any affiliation with any promoters and/or newsletters disseminating information on SNGX, nor is GeoInvesting being paid to post this information. At times, the GeoTeam may trade P&amp;D's on a long or short basis, depending on how we feel the momentum of the stocks will be affected by the efforts of stock promoters and any ensuing dumps.&nbsp;</P> <P><IMG alt="" src="http://geoinvesting.com/wp-content/uploads/2015/06/SNGX-pd.jpg" width=503 height=5218></P>/companies/sngx_soligenix__inc_/research&item=5296852967Wed, 02 Jan 2013 05:00:00 GMTFDA Grants Soligenix Orphan Drug Designation for OrbeShield&#8482; for Treatment after Exposure to a Radiological Disaster. (<A href="http://www.prnewswire.com/news-releases/fda-grants-soligenix-orphan-drug-designation-for-orbeshield-for-treatment-after-exposure-to-a-radiological-disaster-185404662.html">source</A>)/companies/sngx_soligenix__inc_/research&item=52967